Trial Profile
Phase II Trial of Effect of Metreleptin Therapy in Severe Insulin Resistance
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Insulin resistance
- Focus Therapeutic Use
- 15 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2021 Results (n=11) from Metreleptin Study (NCT00085982) and Natural History Study Design (NCT0001987) published in the Journal of Clinical Endocrinology and Metabolism
- 23 Jan 2015 Planned primary completion date changed from 1 Dec 2099 to 1 Jan 2030 as reported by ClinicalTrials.gov record.